A widely prescribed generic medication for overactive bladder has been pulled from the market in one lot after testing found nitrosamine impurities above the limit regulators recommend. The recall covers 25 milligram mirabegron extended-release tablets in 30-count bottles distributed by Zydus Pharmaceuticals (USA) Inc., and it was initiated on August 5.
Federal records classify the action as a Class II recall. The FDA uses that designation for products where exposure may cause temporary or medically reversible health effects, or where the probability of serious harm is remote. It sits below the agency's most serious Class I category.
For adults who fill a mirabegron prescription, the practical question is narrow. This is one lot from one manufacturer, and the medication itself has not been withdrawn. Patients can check a bottle in a few seconds without changing anything about their treatment.
The Bottle Code That Identifies the Recalled Lot
The recalled product is identified by lot code E408618, National Drug Code 70710-1159-3, and an expiration date of November 30, 2026. It covers 25-milligram tablets sold in bottles of 30. Manufacturing traces to a Zydus Lifesciences facility in Matoda, Ahmedabad, India.
Other strengths of mirabegron, other lot numbers, and products from other manufacturers are not part of this recall. Neither is the brand-name version, Myrbetriq.
Patients holding an affected bottle can contact the dispensing pharmacy about a refund or replacement. Pharmacies generally receive recall notices directly from distributors and can confirm whether a specific fill came from the recalled lot. The action is cataloged in the agency's enforcement report database.
An Impurity That Cannot Be Seen or Tasted
Unlike a recall for broken tablets or foreign material, this one involves a chemical that does not change how a pill looks. The recall was initiated because nitrosamine impurities exceeded the level recommended by the FDA.
Nitrosamines are a family of compounds common in water and in foods, including cured and grilled meats, dairy products, and vegetables, and everyone is exposed to them to some degree. They have also been found as unwanted byproducts in pharmaceutical manufacturing and have driven a long series of recalls affecting blood pressure medicines, heartburn drugs, and other classes over the past several years.
The FDA has been consistent about the scale of the risk. Nitrosamine impurities may raise cancer risk with exposure above acceptable levels over long periods, but the agency has said a person taking a drug containing nitrosamines at or below the acceptable daily intake limits every day for 70 years is "not expected to have an increased risk of cancer."Those limits are set internationally with that kind of lifetime exposure in mind.
That framing is important for reading this recall correctly. A single lot exceeding a specification is a manufacturing quality failure. It is not evidence that anyone who took those tablets will develop cancer. Manufacturers are responsible for detecting and limiting these impurities under FDA guidance on nitrosamine control.
Patients Who Rely on Overactive Bladder Treatment
Mirabegron is a beta-3 adrenergic agonist approved for overactive bladder in adults with urinary urgency, frequency, and urge incontinence. It is also approved for neurogenic detrusor overactivity in pediatric patients aged 3 and older who weigh at least 35 kilograms.
Overactive bladder is far more common with age, and the medication is often taken long-term. Many patients moved to mirabegron because older anticholinergic bladder drugs caused side effects such as dry mouth, constipation, or cognitive complaints, which makes it a meaningful option for older adults in particular.
Because it is a generic, Mirabegron is dispensed under multiple labels and through multiple distributors. Patients who use mail-order pharmacies or who receive 90-day supplies may want to check the bottle in their cabinet rather than assuming a recent fill is unaffected.
Steps for Patients Before the Next Refill
The single most important point is that no one should stop taking a prescribed bladder medication because of a recall notice. The FDA advises patients taking prescription medications with potential nitrosamine impurities not to stop and to raise concerns with their health care professional instead.
The reasonable sequence is to check the bottle against the lot code, contact the pharmacy if it matches, and ask whether a replacement from an unaffected lot is available. Pharmacists may be able to dispense the same medication from a lot that has not been recalled.
Anyone concerned that their symptoms are related to a medication should speak with a clinician rather than adjusting the dose independently. Patients can also report problems through the FDA's MedWatch program, which feeds the agency's safety surveillance.
Recall classifications and status updates are published in the FDA's drug recalls listings. Because enforcement reports are updated on a rolling basis, the scope of an action can change after it is first posted.
Key Questions Answered
Which lot is affected? Mirabegron extended-release tablets, 25 milligrams, in 30-count bottles, with lot code E408618, National Drug Code 70710-1159-3, and an expiration date of November 30, 2026.
What does a Class II recall mean? The FDA applies this classification when exposure to a product may cause temporary or medically reversible health effects, or when the probability of serious harm is remote.
Should patients stop taking mirabegron? No. The FDA advises patients not to stop prescription medications over potential nitrosamine impurities. Check the bottle, then talk to the pharmacy.
What are nitrosamine impurities? They are compounds that can form as unwanted byproducts during drug manufacturing and are also common in some foods and water. Regulators set daily intake limits based on lifetime exposure.
Does taking the recalled lot mean someone will get cancer? No. The FDA has stated that daily exposure at or below acceptable intake limits over 70 years is not expected to raise cancer risk. Exceeding a specification is a quality failure, not a diagnosis.
Who should pay closest attention? Anyone dispensed 25 mg mirabegron in a 30-count bottle, particularly older adults and long-term users who may have several months' supply on hand.
Where can patients get a replacement? The dispensing pharmacy can confirm the lot and may be able to dispense the same medication from a lot that was not recalled.
